Final NICE no for Avastin in ovarian cancer
NICE has once again rejected Roche’s Avastin, the world’s biggest selling cancer drug, this time for its new licence in ovarian cancer.
Read MoreAuthor: Ben Adams
Rawlins ‘burns credibility’ with biotech move
The former chairman of NICE Sir Michael Rawlins has attracted criticism after taking up the position of a board member at US biotech firm Intra-Cellular Therapies.
Read MoreTen UK charities win GSK accolade and cash boost
Ten charities have won GlaxoSmithKline’s IMPACT Awards for 2013 after being recognised for helping the UK with its health and well-being.
Read MoreNICE thumbs up for new Astellas bladder drug
In final draft guidance NICE is recommending Astellas’s Betmiga (mirabegron) for the treatment of overactive bladder syndrome in patients for whom antimuscarinic drugs – the established treatment for the condition – are not suitable.
Read MoreShire’s shenanigans continue; guilty of 10 Code breaches
Shire has once again fallen foul of the ABPI Code of Conduct after using a press release for its Gaucher’s disease drug Vpriv to knock a rival product.
Read More- Leuko device to remotely monitor cancer patients during chemotherapy
- Ten-minute brain scan could improve diagnosis for paediatric brain cancer
- Francis Crick, UCL and AZ identify why treatment fails for NSCLC patients
- Royal Marsden launches first UK genome testing facility to improve testing for cancer
- Sysmex receives Longitude Prize on AMR for antimicrobial testing system
